| Nov 12 |
Sangamo Therapeutics GAAP EPS of $0.04 beats by $0.08, revenue of $49.41M beats by $24.34M
|
| Nov 12 |
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
|
| Nov 12 |
Earnings Scheduled For November 12, 2024
|
| Nov 4 |
Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast
|
| Nov 1 |
individual investors who own 55% along with institutions invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) saw increase in their holdings value last week
|
| Oct 23 |
Sangamo: Fabry Disease Gene Therapy Moves Forward With Positive FDA Regulatory Development
|
| Oct 23 |
Merck acquires cancer drug startup; Elevidys ex-US sales rise
|
| Oct 22 |
Sangamo stock rallies 37% on FDA update for Fabry disease drug
|
| Oct 22 |
Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025
|
| Oct 21 |
Sangamo Follow-Up: Giro-Vec And STAC-BBB? Check. Isa-Vec... Trifecta Soon?
|
